Anumana Patent for Non-Invasive ECG and Echo Monitoring with Machine Learning

Anumana, Inc. filed patent application US20260096783A1 on April 9, 2026 (filed October 4, 2024 as Application No. 18907123) for an apparatus and method combining non-invasive ECG and echocardiogram data with machine learning to generate simulated invasive measurement data. The system fuses ECG and echo measurements and uses trained ML models to produce data equivalent to invasive cardiac measurements, transmitting results to remote devices. CPC classifications span cardiac monitoring (A61B 5/7267, A61B 5/256, A61B 5/346), medical imaging (G06T 15/005), and health informatics (G16H 50/20, G16H 50/70).

Systems and Methods for Automatic State Estimation of Current Imaging Exam Using User Actions on Console Screen

USPTO published patent application US20260096786A1 filed by seven inventors including SIVA CHAITANYA CHADUVULA, EKIN KOKER, OLGA STAROBINETS, RANJITH NAVEEN TELLIS, SANDEEP MADHUKAR DALAL, THOMAS ERIK AMTHOR, and YUECHEN QIAN. The application covers a system for automatically estimating the state of a medical imaging examination using video analysis and a state machine algorithm implemented in electronic processors, with results displayed on an electronic processing device. The filing date was September 19, 2023, with application number 19112526.

System to Monitor and Manage Patient Hydration via Plethysmograph Variability Index in Response to Passive Leg Raising

The USPTO published patent application US20260096773A1 on April 9, 2026, filed September 2, 2025, for a system using a processor to predict fluid responsiveness or unresponsiveness in patients based on plethysmograph variability parameters and limb-elevation fluid responsiveness parameters, then causing administration or termination of fluid delivery based on the combined prediction. The named inventors are Massi Joe E. Kiani, Bilal Muhsin, and Keith Ward Indorf. CPC classifications include A61B 5/4848 and G16H 20/17 (Health Informatics), with the application originating from US application number 19316927.

Bayesian Denoising for Retrospective PISA Detection in Analyte Traces

The USPTO published patent application US20260096780A1 for a Bayesian denoising method to detect pressure-induced sensor artifacts (PISA) in analyte traces. The method receives measured analyte data samples from a sensor, generates a reconstructed trace with confidence windows using a Bayesian algorithm, and compares the two to identify artifacts outside the confidence interval. Inventors include Andrea Facchinetti, Simone Del Favero, Giovanni Sparacino, Elena Idi, Eleonora Manzoni, and Nunzio Camerlingo. The application (No. 18908001) was filed October 7, 2024 and published April 9, 2026.

Insulin Dosage Patent Application by Stone, Mikhno, Turksoy, and Grossman

USPTO published patent application US20260096775A1 titled 'Open Loop Intelligent Dosing' on April 9, 2026. The application covers systems and techniques for generating personalized insulin dosage recommendations by building a physiological model from a patient's historical glucose and insulin data, estimating the impact of meal consumption on glucose levels, and outputting a personalized meal bolus insulin dose recommendation. The application was filed on September 16, 2025 under Application No. 19330568, with four named inventors: Michael P. Stone, Arthur Mikhno, Kamuran Turksoy, and Benyamin Grossman. This is a published patent application record; it has not yet been granted and creates no immediate compliance obligations.

Pain Detection Method Using Sensors in Personal Care Devices

USPTO published patent application US20260096772A1 titled "Pain Detection Method" on April 9, 2026, filed by six inventors including Amir Hussein Rmaile, Mark Thomas Johnson, and others. The application (No. 19114825, filed September 26, 2023) covers a method for objectively measuring user pain during personal care sessions using force and/or motion sensors integrated into personal care devices such as oral care devices. The sensor data patterns can infer pain levels, pain reaction events at specific points or locations, and increased sensitivity in certain body areas.

Ring-Type Wearable Device for Biometric Health Monitoring

USPTO published patent application US20260096777A1 on April 9, 2026, filed on May 8, 2025, by inventors Thomas Voigt and Swagatika Bhattacharya. The application covers a ring-type wearable device with multiple LEDs and photodetectors for biometric health monitoring. The published application does not grant any rights and represents an early-stage IP filing rather than an issued patent.

Nant Holdings IP Files Neoepitope Validation Patent, US20260110686A1

Nant Holdings IP, LLC has published patent application US20260110686A1, covering systems and methods for predicting MHC presentation of a neoepitope of a tumor or for predicting an immune response against an MHC presented neoepitope of a tumor. The application names inventors Kayvan Niazi and Nicholas J. Witchey, was filed on 2025-10-21 under Application No. 19364620, and was published on April 23, 2026. CPC classifications span immunology, peptides, and diagnostics (G01N, C07K, A61K series).

Glycoprotein Glycan Modification Method

Amgen Inc. has filed patent application US20260110013A1 covering a method for manipulating the fucosylated glycan content on recombinant proteins. The application, filed on October 22, 2025 (Application No. 19365891), was published on April 23, 2026. Inventors Daniel R. Leiske and Michael T. Trentalange are credited with the invention, which has implications for biopharmaceutical development and glycoprotein-based therapeutic manufacturing.

Methods for Standardizing Lectin Reagents, IgA1 Calibration Standards, and Quantitative Measurement of Galactose-Deficient IgA1

USPTO published patent application US20260110695A1 assigned to Reliant Glycosciences, LLC, covering methods for standardizing lectin reagents and measuring galactose-deficient IgA1 (Gd-IgA1) as a biomarker for IgA nephropathy. The application includes a lectin-based ELISA assay kit using standardized GalNAc-specific lectins such as biotinylated Helix pomatia agglutinin (HPA) or Helix aspersa agglutinin (HAA). Filed October 22, 2025, with inventors William Placzek, Thomasz Szul, Matthew Renfrow, Janusz Tucholski, and Jan Novak.

Mixture Of Interferon Alpha 2B With Modified Sequences Thereof

PharmaEssentia Corporation filed USPTO patent application US20260109750A1 for interferon-polymer conjugates to treat three rare blood disorders: idiopathic myelofibrosis, polycythaemia vera, and essential thrombocythaemia. The application was submitted on October 17, 2025, listing six inventors including Ko-Chung Lin and Shin-Jye Lee. CPC classifications include C07K 14/56, C12P 21/02, G01N 33/6824, and A61K 38/00.

US20260108577A1: Biotic Superparamagnetic Nanoparticles from Colchicum Ritchii

USPTO published patent application US20260108577A1 on April 23, 2026, disclosing a method for preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract combined with ferric chloride solution and sodium hydroxide solution. The application names VEERAMANI CHINNADURAI, KHALID S. AL-NUMAIR, and MOHAMMED A. ALSAIF as inventors, with a filing date of October 17, 2024, and application number 18918527. CPC classifications indicate pharmaceutical applications including weight management (A61P 3/04) and diabetes treatment (A61P 3/10).

BioDevas Laboratoires Patent for Aromatic Plant Extract Flea Treatment Composition

BioDevas Laboratoires has been granted USPTO Application US20260108576A1 for a composition against ectoparasites, specifically fleas affecting domestic mammals. The composition comprises a mixture of extracts from aromatic plants, including lemon balm, thyme, rosemary, wormwood, and lemongrass. The application was filed on December 22, 2025, under Application No. 19428445, with inventors François BLUA and Jean Louis BLUA. The patent covers veterinary and pharmaceutical compositions incorporating the extract mixture, along with animal food products containing the composition and methods for preparing and administering the composition for flea prevention or treatment.

Method for Preparing Biotic Superparamagnetic Nanoparticles Derived from Colchicum Ritchii

USPTO has published patent application US20260108578A1 for a method of preparing biotic superparamagnetic nanoparticles using Colchicum ritchii plant extract. The application, filed on January 17, 2025 by inventors Veeramoni Chinnadurai, Khalid A. Al-Numair, and Mohammed A. Alsaif, describes combining the plant extract with ferric chloride solution followed by sodium hydroxide to form superparamagnetic nanoparticles. The invention is classified under CPC codes A61K 36/88, A61K 9/5115, A61K 9/5192, A61K 47/02, A61P 3/04, and A61P 3/10, indicating applications in pharmaceutical preparations for metabolic disorders.

Nrf2 Activation Compositions, Treat Inflammation, Oxidative Stress

USPTO published patent application US20260108575A1 on April 23, 2026, filed by Brooks Michael Hybertson and Joe Milton McCord under Application No. 19370063. The application covers compositions containing phytochemicals that activate Nrf2 pathways for preventing or treating health conditions associated with inflammation or oxidative stress. The filing date was October 27, 2025, and CPC classifications include A61K 36/53, A61K 31/352, A61K 36/906, and A61K 45/06.

Calluna Vulgaris for Urinary Tract Infection Treatment

USPTO published patent application US20260108573A1 by inventor Heather Florio on April 23, 2026, covering methods and compositions of Calluna vulgaris for the prevention and treatment of urinary tract infections. The application (No. 19322118) was filed on September 8, 2025 and classifies under CPC codes A61K 36/45, A61K 9/14, and A61P 13/02.

US20260108574A1 Herbal Composition for Metabolic Disorders

The USPTO has published patent application US20260108574A1, filed October 16, 2025 by M/S Natural and Essential Oils Private Limited, disclosing a herbal composition for treating metabolic disorders in mammals including central obesity, high blood pressure, high blood sugar, stress-induced fatigue, and type 2 diabetes. The composition comprises extracts of Dolichos lablab, Achyranthes aspera, and Cinnamomum zeylanicum or Cinnamomum cassia, standardized to contain proanthocyanidins, saponins, polyphenols, and tannins. The application describes methods of preparation and therapeutic effects including enhanced adiponectin and HDL levels.

Ophthalmic Formulations, Pelthos Therapeutics, Eye Pain

Pelthos Therapeutics Inc. filed US Patent Application US20260108500A1 on October 22, 2025, covering ophthalmic formulations comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide or a pharmaceutically acceptable salt thereof. The application names four inventors: Eric D. Lang, Simon Paul Chandler, Deshou Jiang, and Richard Malamut. The formulations are directed to treatment of various eye conditions including pain.

Ponesimod Patent with Teriflunomide or Leflunomide

USPTO published Application US20260108501A1 on April 23, 2026, covering a pharmaceutical combination of ponesimod with either teriflunomide or leflunomide. Inventors are Martine Clozel and Laetitia Pouzol, with filing date December 22, 2025, and application number 19429084. The combination is classified under CPC A61P 25/28, indicating neurological therapeutic applications.

Method of Eradicating Ticks That Attach to Humans Using Lotilaner Formulations

USPTO published patent application US20260108498A1 filed December 22, 2025 (Application No. 19429133) for methods of treating or preventing Lyme disease and other vector-borne diseases via administration of lotilaner, an isoxazoline anti-parasitic therapeutic agent. The application discloses formulations and dosing regimens for eradicating ticks that attach to humans. Named inventors are Bobak Robert Azamian, Douglas Michael Ackermann, Christopher Stivers, and Shawn D. Hickok. CPC classifications indicate pharmaceutical compositions (A61K 31/422, A61K 9/08, A61K 47/26) and antiparasitic applications (A61P 33/14).

Pelthos Therapeutics Injectable Extended-Release Formulation for Pain Treatment

USPTO published patent application US20260108499A1 for Pelthos Therapeutics Inc., filed October 22, 2025, covering injectable pharmaceutical formulations for extended release comprising 2-{[3-(5-chloro-2-{2-chloro-5-fluoro-4-[(1,3-thiazol-4-yl)sulfamoyl]phenoxy}phenyl)propyl]amino}acetamide, or a pharmaceutically acceptable salt thereof. The named inventors are Eric D. LANG, Simon Paul CHANDLER, Deshou JIANG, and Richard MALAMUT (Application No. 19365336). The formulations are intended for treatment of pain or providing peri-operative anesthesia or post-operative analgesia.

Reprogramming Exhausted T Cells, Boosting Cancer Immunotherapy

USPTO published patent application US20260108496A1 disclosing methods for reviving exhausted T cells and enhancing cancer immunotherapy by inhibiting TGFβR1 and/or BMP4 proteins, or using agonists to rescue functional phenotypes of exhausted T cells. The application was filed on 2023-09-14 under application number 19111688 and published on 2026-04-23. Inventors include Hazem Ghoneim.

Nasal Pharmaceutical Composition Treats Chronic Rhinosinusitis

The USPTO has published patent application US20260108489A1, filed October 15, 2025 by inventors Eduardo Roberto Varizat and Daniel Roberto Varizat, covering a new topical nasal pharmaceutical composition for the treatment and prophylaxis of chronic rhinosinusitis (CRS). The composition comprises a homogeneous aqueous suspension containing Rifamycin, fluticasone propionate, oxymetazoline hydrochloride, bacterial antigens, 0.9% saline solution, and pharmaceutical excipients, formulated for nasal spray administration. The inventors claim synergy among the active ingredients producing local antibiotic, anti-inflammatory, decongestant, and immunomodulatory effects at the site of action.

Neuroinnovatech Parkinson's Non-Motor Symptoms Therapeutic Agent, Apr 23, 2026

NEUROINNOVATECH ApS has filed USPTO patent application US20260108494A1 for a therapeutic agent targeting serotonergic or dopaminergic system-related diseases, specifically the mental dysfunction and non-motor symptoms of Parkinson's disease. The application includes a treatment and recurrence-prevention method using a compound represented by formula (1) or a pharmaceutically acceptable salt thereof. Application No. 19423150 was filed on 2025-12-17 with inventors Taro Kato and Satoko Shimizu.

Soft Anticholinergic Esters Treat Sialorrhea, Bodor Labs

Bodor Laboratories, Inc. has filed patent application US20260108491A1 (Application No. 19367341, filed October 23, 2025, published April 23, 2026) covering intra-oral formulations of soft anticholinergic alkyl esters for treating excessive drooling associated with sialorrhea. The formulations are described as anhydrous and configured for intra-oral delivery of an effective amount of at least one soft anticholinergic ester to inhibit sialorrhea. CPC classifications include A61K 31/40 (heterocyclic compounds), A61P 1/02 (stomatological preparations), and C07D 207/10 and C07D 207/12 (pyrrole derivatives).

Siponimod and Beta-Blocker Combination for Treating Autoimmune Disease

The USPTO published application US20260108490A1, a method-of-treatment patent covering siponimod in combination with a beta-blocker for treating autoimmune diseases, filed on December 22, 2025. The application names 11 inventors and classifies the invention under CPC categories including A61K (medicinal preparations) and A61P 37/00 (immunoregulating agents). Pharmaceutical companies developing autoimmune disease therapies should review freedom-to-operate positions regarding S1P receptor modulators combined with cardiovascular agents.

Nocendra Inc. Lipoxin Synthesis Patent Application, Apr 23

Nocendra Inc. filed patent application US20260108486A1 on December 17, 2025, covering methods of synthesizing lipoxin analogs (e.g., lipoxin mimetics) and pharmaceutical compositions comprising these pro-resolving compounds. The application lists Thomas E. Van Dyke and Charles N. Serhan as inventors. The published application includes CPC classifications A61K 31/202 and A61P 1/02.

Ameren Illinois Beneficial Electrification Plan Investigation

The Illinois Commerce Commission has opened an investigation (P2026-0362) into Ameren Illinois Company's Beneficial Electrification Plan to determine whether the utility is achieving the objectives of Section 45 of the Electric Vehicle Act. The case is currently at the Initial stage with Administrative Law Judge action pending. This proceeding will examine Ameren Illinois's compliance with state-mandated electrification requirements.

ICC Investigation of Commonwealth Edison Ratepayer Protections and Cost Recovery Mechanisms

The Illinois Commerce Commission initiated investigation P2026-0364 on April 23, 2026, examining possible ratepayer protections and cost recovery mechanisms for servicing large demand project applicants or customers of Commonwealth Edison Company. The case is classified as an Investigation - Miscellaneous Investigation with Initial status, with an Administrative Law Judge assigned. No specific compliance obligations or deadlines have been established at this stage of the proceeding.

Beneficial Electrification Plan Investigation, Commonwealth Edison Company

The Illinois Commerce Commission initiated an investigation into Commonwealth Edison Company's Beneficial Electrification Plan to determine whether the objectives of Section 45 of the Electric Vehicle Act are being achieved. The investigation was opened on April 23, 2026, with an Administrative Law Judge assigned and action pending. This is a standard regulatory review of utility compliance with state electrification mandates.

Marcus Quinn vs Nicor Gas Company - Service Complaint

A complaint has been filed by Marcus Quinn against Northern Illinois Gas Company, doing business as Nicor Gas Company, regarding the utility's alleged failure to provide required policies in Chicago Heights, Illinois. The case was filed on April 23, 2026 and is currently in initial status with an Administrative Law Judge action pending. The Illinois Commerce Commission will adjudicate the complaint through its administrative process.

Dennis Woiwood vs Peoples Gas Light and Coke Company

A complaint was filed with the Illinois Commerce Commission on April 23, 2026 by Dennis Woiwood against The Peoples Gas Light and Coke Company. The complaint, docketed as P2026-0366, concerns account changes at the Chicago gas utility and is categorized as a billing dispute under the Commission's complaint procedures for gas utilities. The case is currently in initial status with an Administrative Law Judge action pending.

NTSB Calls for Alcohol Detection Systems in School Buses and Renews Call for Student Seat Belts

NTSB completed its investigation of a March 4, 2024 school bus rollover crash in Millstone, West Virginia, finding that the driver's blood alcohol concentration was 0.161 g/dL—twice the legal limit—and that three students sustained serious injuries while 16 others had minor injuries after being thrown from seats. NTSB recommended that NHTSA require all new school buses to be equipped with vehicle-integrated alcohol detection systems and renewed its call for states to require passenger lap/shoulder belts on large school buses, citing 118 school bus drivers cited or arrested nationwide from 2015–2019 for alcohol or drug impairment.

Jenna Gadalha vs Rocky Mountain Power - Formal Complaint, Docket No. 26-035-22

A Utah consumer, Jenna Gadalha, filed a formal complaint against Rocky Mountain Power with the Utah Public Service Commission under Docket No. 26-035-22. The PSC issued an Action Request to Rocky Mountain Power with a response deadline of May 15, 2026, and opened a public comment period. The docket references an underlying informal complaint as an attachment. This individual complaint proceeding does not establish industry-wide compliance obligations but may reflect service or billing disputes with the utility.

EPA Corrects Docket, Extends Comment Period for WRB Refining Hazardous Waste Exclusion

The EPA published a correction on April 22, 2026 to a March 26, 2026 proposed rule regarding WRB Refining LP's hazardous waste exclusion petition. The document corrects a docket number from EPA-R06-RCRA-2025-13174 to EPA-R06-RCRA-2026-2641 and extends the public comment period by 22 days to May 20, 2026. The correction applies to the delisting petition for the Borger, Texas refinery. Comments must reference the corrected docket number.

Virginia VOC Definition Approved Under Air Quality SIPs

The EPA is approving Virginia's SIP Revision A23, which updates the definition of volatile organic compound (VOC) in the Virginia Administrative Code to align with the federal definition in 40 CFR 51.100(s). The revision adds trans-1,1,1,4,4,4-hexafluorobut-2-ene (HFO-1336mzz(E); CAS number: 66711-86-2) to the list of compounds excluded from the regulatory definition of VOC. The EPA determined on February 8, 2023 that HFO-1336mzz(E) is of negligible reactivity and makes a low contribution to tropospheric ozone formation. This final rule is effective May 26, 2026.

EPA TSCA Substantial Risk Notification, Ends May 26

The EPA has submitted an information collection request for the TSCA Section 8(e) Substantial Risk Notification program (EPA ICR Number 0794.18, OMB Control Number 2070-0046) to OMB for review, proposing to extend the currently approved ICR currently effective through April 30, 2026. This notice provides an additional 30-day public comment period ending May 26, 2026. Affected entities include those classified under NAICS Codes 325 (Chemicals and Allied Products) and 32411 (Petroleum and Coal Products Manufacturing), with an estimated 40 respondents, total annual burden of 27,883 hours, and total estimated cost of $2,829,844 per year.

Forty-Ninth Update to Federal Agency Hazardous Waste Compliance Docket Under CERCLA

The EPA has published its forty-ninth update to the Federal Agency Hazardous Waste Compliance Docket under CERCLA, identifying federal facilities that manage hazardous waste or have released reportable quantities of hazardous substances. This update adds two facilities to the Docket, with zero deletions and zero corrections since the previous update published on November 28, 2025. The list is current as of April 1, 2026.

EPA ICR on Human Research Protocols Submitted to OMB for Review

The EPA has submitted an Information Collection Request (ICR) to the Office of Management and Budget regarding the submission of protocols and study reports for environmental research involving human subjects. The agency is seeking public comment on this renewal request, which covers the collection of information related to human subjects research protocols. The comment period closes on May 26, 2026, providing 33 days for interested parties to submit feedback.

EPA Requests Comments on CERCLA Emergency Response Reimbursement ICR for Local Governments

The EPA has opened a 60-day public comment period through June 22, 2026, on a proposed information collection request (ICR) under the Paperwork Reduction Act. The ICR covers the Application for Reimbursement to Local Governments for Emergency Response to Hazardous Substance Releases under CERCLA Section 123. Comments may be submitted via Regulations.gov at docket EPA-HQ-OLEM-2018-0081. The collection allows qualifying local governments to seek reimbursement for emergency response costs incurred at Superfund cleanup sites.

EPA Submits TSCA 8(e) Substantial Risk Notification to OMB

The EPA has submitted an information collection request under TSCA Section 8(e) to the Office of Management and Budget for review and approval. The notice seeks public comment on requirements for manufacturers and importers to notify EPA of substantial risk of injury to health and the environment. The comment period closes in 33 days on May 26, 2026, via Regulations.gov under docket EPA-HQ-OLEM-2018-0081-0022.

EPA Proposes Approving Kentucky State Plan for Municipal Solid Waste Landfill Emissions

EPA Region 4 is proposing to approve Kentucky's State Plan for Designated Facilities and Pollutants under 40 CFR Part 62, which governs control of emissions from existing municipal solid waste landfills. The proposal, published in the Federal Register on April 23, 2026, opens a public comment period ending May 26, 2026. If approved, Kentucky would assume primary implementation and enforcement authority for landfill emission standards from EPA.

EPA Seeks Comment on Contractor Access to TSCA CBI

The EPA is seeking public comment on an information collection request to allow contractors access to TSCA Confidential Business Information (CBI) submitted by regulated entities. Comments must be submitted by May 26, 2026, a 33-day comment period from the April 23, 2026 Federal Register publication. The request is submitted to the Office of Management and Budget under the Paperwork Reduction Act.

Gulf LNG Liquefaction Company, LLC Request for Extension of Export Commencement Deadline

The Department of Energy has published a notice announcing that Gulf LNG Liquefaction Company, LLC has requested an extension of its LNG export commencement deadline under Docket No. 12-101-LNG. The notice opens a 33-day public comment period, closing May 26, 2026, during which interested parties may submit comments via Regulations.gov. The DOE is seeking input on whether to grant the extension request.

FCC Seeks Public Comment on Information Collection Under OMB 3060-0298

The Federal Communications Commission published a notice in the Federal Register on April 23, 2026, requesting public comment on an information collection under OMB Control Number 3060-0298. The notice states that comments are due within 60 days, with a comment close date of June 22, 2026. This action is part of the FCC's compliance with the Paperwork Reduction Act and does not impose new substantive requirements on regulated entities.

FCC Proposes Rules for Call Center Onshoring

The Federal Communications Commission has published a proposed rule titled 'Improving Customer Service and Protecting Consumers Through Onshoring' in CG Docket Nos. 26-52, 17-59, 02-278, and 22-2, FCC 26-16. The proposal seeks public comment on requiring call centers to be onshored (located within the United States) or to disclose offshore locations to consumers. The document is open for public comment for 33 days, with comments due by May 26, 2026.

Presidential Determination on Grid Infrastructure, Defense Production Act

President Trump issued Presidential Determination No. 2026-10 on April 20, 2026, invoking Section 303 of the Defense Production Act of 1950 to designate grid infrastructure—including transformers, transmission lines, substations, circuit breakers, power electronics, and related manufacturing equipment—as industrial resources and critical technology items essential to national defense. The determination references Executive Order 14156 (Declaring a National Energy Emergency) and finds that America's aging and constrained electric grid, coupled with overreliance on imported equipment and long production lead times, poses a vulnerability in the event of war, disaster, or economic disruption.

Presidential Determination on Large-Scale Energy Infrastructure Under Defense Production Act

President issued Determination No. 2026-09 on April 20, 2026, invoking Section 303 of the Defense Production Act to designate large-scale energy and energy-related infrastructure—including development, manufacturing, deployment, site acquisition, permitting, and domestic manufacturing capacity—as industrial resources essential to national defense. The determination cites financing risks, regulatory delays, and market barriers as reasons that private industry cannot provide these capabilities without presidential action. The finding enables expanded executive authority to address domestic energy infrastructure gaps under the declared national energy emergency.

Presidential Determination on Natural Gas Infrastructure Under Defense Production Act

President issued Determination No. 2026-12 on April 20, 2026, designating natural gas and LNG capacity—including gathering and transmission pipelines, compression, processing plants, underground storage, LNG liquefaction, storage, marine load, export facilities, and critical distribution infrastructure—as industrial resources essential to national defense under Section 303 of the Defense Production Act. The determination finds that without presidential action, U.S. industry cannot reasonably provide these capabilities in a timely manner due to financing constraints and long-lead construction schedules. This builds on Executive Order 14156 declaring a National Energy Emergency on January 20, 2025.

DOJ Antitrust Division Finds DOE Voluntary Agreement May Proceed Under DPA

The Acting Assistant Attorney General for the Antitrust Division has completed the required review under section 708 of the Defense Production Act of 1950 for the Department of Energy's proposed revised Implementing Voluntary Agreements Under the Defense Production Act. The finding concludes that the purposes of section 708(c)(1) of the DPA may not reasonably be achieved through a voluntary agreement having less anticompetitive effects or without any voluntary agreement. Following publication of this notice, the proposed revised Voluntary Agreement may become effective. Participants acting within the scope of a valid voluntary agreement and plan of action gain an antitrust law defense for their coordinated activities.